These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
18. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint. Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275 [TBL] [Abstract][Full Text] [Related]
19. D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment. Schröder J; Silvestri S; Bubeck B; Karr M; Demisch S; Scherrer S; Geider FJ; Sauer H Biol Psychiatry; 1998 May; 43(9):660-5. PubMed ID: 9582999 [TBL] [Abstract][Full Text] [Related]
20. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study. Pilowsky LS; Busatto GF; Taylor M; Costa DC; Sharma T; Sigmundsson T; Ell PJ; Nohria V; Kerwin RW Psychopharmacology (Berl); 1996 Mar; 124(1-2):148-53. PubMed ID: 8935810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]